Literature DB >> 12384841

Antifungal resistance in pathogenic fungi.

Sofia Perea1, Thomas F Patterson.   

Abstract

Pathogenic fungi are the cause of life-threatening infections in an increasing number of immunocompromised patients. The intrinsic resistance to antifungal therapy observed in some genera, along with the development of resistance during treatment in others, is becoming a major problem in the management of these diseases. We reviewed the epidemiology of the most common systemic fungal infections for which antifungal resistance is a potential problem, the mechanisms of antifungal resistance, the correlation between in vitro susceptibility testing and clinical outcome, and the clinical implications of antifungal resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384841     DOI: 10.1086/344058

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  56 in total

1.  Rapid quantification of drug resistance gene expression in Candida albicans by reverse transcriptase LightCycler PCR and fluorescent probe hybridization.

Authors:  Joao P Frade; David W Warnock; Beth A Arthington-Skaggs
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

Review 2.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

3.  Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.

Authors:  D Andes; A Forrest; A Lepak; J Nett; K Marchillo; L Lincoln
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling.

Authors:  D Andes; A Lepak; J Nett; L Lincoln; K Marchillo
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 5.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 6.  Will resistance in fungi emerge on a scale similar to that seen in bacteria?

Authors:  H Hof
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-19       Impact factor: 3.267

7.  Susceptibility of Candida albicans Isolated from Blood to Wickerhamomyces anomalous Mycocins.

Authors:  Ana Paula Paris; Cristiane Persel; Cleber Fernando Serafin; Rita de Cássia Garcia Simão; Rinaldo Ferreira Gandra
Journal:  Curr Microbiol       Date:  2016-09-16       Impact factor: 2.188

8.  Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.

Authors:  Sabrina Schubert; P David Rogers; Joachim Morschhäuser
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

9.  Metabolism and resistance of Fusarium spp. to the manzamine alkaloids via a putative retro pictet-spengler reaction and utility of the rational design of antimalarial and antifungal agents.

Authors:  Noer Kasanah; Lorelei Lucas Farr; Abbas Gholipour; David E Wedge; Mark T Hamann
Journal:  Mar Biotechnol (NY)       Date:  2014-02-20       Impact factor: 3.619

10.  Studies on the antifungal properties of N-thiolated beta-lactams.

Authors:  Marci O'Driscoll; Kerriann Greenhalgh; Ashley Young; Edward Turos; Sonja Dickey; Daniel V Lim
Journal:  Bioorg Med Chem       Date:  2008-06-25       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.